US Needs National Diagnostic Testing Plan for Public Health Threats
Allowing nontraditional laboratories to perform diagnostic testing in a potential pandemic situation was one of the nearly 100 actions proposed by a panel of experts, according to results of a new report published by the Government Accountability Office (GAO).
The new report ultimately yielded four recommendations from the GAO to the Department of Health and Human Services (HHS), with two action items. One of these called for the creation of a national diagnostic testing strategy for infectious diseases with pandemic potential. Another called for the creation of a national diagnostic testing forum that would include a range of expert testing stakeholders from HHS and component agencies, but also the public and private sectors, nonprofit organizations, and academia.
The other two main recommendations were that the national diagnostic testing strategy, once created, be updated regularly with lessons learned from infectious disease threats, other public health threats, or relevant preparedness exercises; and that the national diagnostic testing forum, once created, meet regularly, including both before and during infectious disease threats with pandemic potential, before and during other public health threats deemed relevant, or any related preparedness exercises.
'Pandemics pose an ever-present threat to American lives, national security, and economic interests, and diagnostic testing is critical to tracking infectious disease and helping reduce potential death rates,' said Mary Denigan-Macauley, director of Public Health for the GAO, in an interview.
'Testing helps us know where the disease is, how it is spreading and if it is gone,' Denigan-Macauley said. During the COVID-19 pandemic and the recent mpox outbreaks, the US Department of HHS struggled to lead the nation's testing efforts, and taking action to improve testing protocols now can boost preparedness for the next infectious disease emergency, Denigan-Macauley said.
Diseases know no borders, she added. 'A strain of highly pathogenic avian influenza is widespread in wild birds around the globe and is already on our doorstep, causing outbreaks in poultry and US dairy cows, with several recent human cases in US dairy and poultry workers,' Denigan-Macauley said. 'Tracking these and other diseases is critical so we can be prepared and implement measures to control their spread,' she emphasized.
Cooperative Planning Will Promote Current Information
Infectious disease testing is not for the federal government to do alone; everyone from the doctor who tests the patient to local, state, and federal health officials should understand the national diagnostic testing strategy so they can work together, said Denigan-Macauley. 'We don't want key stakeholders working in silos that are fragmented and disjointed; this prevents us from understanding what is happening nationally to control a disease,' she said.
'A national diagnostic testing strategy and coordinating group could help the nation avoid some of the challenges faced during previous public health emergencies,' Denigan-Macauley told Medscape Medical News . 'For example, we found that the federal government did not always coordinate its updates to COVID-19 testing guidance with external stakeholders, such as healthcare professional organizations, which led to confusion and disagreement in the practice community,' she said. However, a national testing strategy could establish specific processes for coordination and collaboration related to testing guidance updates, she noted. 'A national coordinating group could then facilitate real-time communication of the updates, which would help ensure that frontline providers are prepared to implement new guidance upon its release,' she added.
The current fragmented state of diagnostic testing efforts across numerous government agencies is a barrier to a national strategy, Denigan-Macauley told Medscape Medical News . 'Fragmentation refers to circumstances in which more than one agency is involved in the same broad area,' she said. 'Our states — simply by the way we are set up as a nation — also have differing capabilities, goals and their own health systems causing further fragmentation,' she explained. Establishing a testing coordinating group and implementing practices for interagency collaboration can help manage fragmentation and overcome this barrier, she said.
Research Gaps
The experts consulted on the report suggested several areas in need of additional research, including determining the types of diagnostic testing required for different types of pathogens, developing diagnostic tests with longer shelf lives, evaluating the new generations of diagnostic testing equipment, and understanding the human behaviors that drive compliance with diagnostic testing guidance, said Denigan-Macauley.
A Specialist's Take
Having a national diagnostic testing strategy would allow the US to cope more efficiently with the next pandemic, said Romney M. Humphries, PhD, D(ABMM), M(ASCP), professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center, Nashville, Tennessee, in an interview.
The COVID-19 pandemic was challenging in many ways, including the inability of many public health labs to handle the surge in testing needs, said Humphries.
'A national diagnostic testing strategy would promote building an infrastructure and developing partnerships among labs,' said Humphries. In addition, developing a universal approach to testing and standardized testing protocols, as are common in European countries, would streamline the process and facilitate such partnerships, she said.
However, funding is a significant barrier to implementing any national diagnostic testing strategy, Humphries noted. Funding for various public health initiatives is being reduced or eliminated, but a national diagnostic testing strategy should be prioritized given the benefit to public health in general and the value in the event of a pandemic or other public health crisis, she said.
Looking ahead, improvements in management and operations at the federal, state, and local level are needed to make a national diagnostic testing strategy successful, Humphries told Medscape Medical News .
Although no action has yet been taken to create a national diagnostic testing strategy, 'HHS officials said they are taking some steps to improve diagnostic testing related to the actions suggested by experts,' according to the GAO website outlining the report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Investors should consider this growth stock… it's SpaceX's competition
Rocket Lab (NASDAQ:RKLB) is a US-listed growth stock that gives investors rare access to the commercial space sector. As a vertically integrated launch and space systems provider, Rocket Lab is often compared to SpaceX in its ambition and capabilities. But there's one crucial difference: you can actually buy shares in Rocket Lab, while SpaceX remains private. Rocket Lab delivers launch services, builds small and medium-class rockets, and manufactures spacecraft components for a range of commercial, government, and defense customers. With rapid revenue growth, an impressive order book, and expansion into new markets, Rocket Lab offers public market investors a way to participate in the booming space economy. It targets many of the same opportunities as its more famous, privately held peer. Rocket Lab and SpaceX operate in the same commercial space sector but differ significantly in scale, maturity, and valuation. Rocket Lab's market cap is currently $12.85bn, with trailing 12 months (TTM) revenue of approximately $460m. Despite strong growth — revenue nearly doubled from $240m in 2023 — Rocket Lab remains a smaller, earlier-stage player focused on small to medium launch vehicles and spacecraft manufacturing. Its valuation multiples are extremely high, with a forward price-to-sales ratio of 22.3 times, reflecting investor optimism. SpaceX, by contrast, is a far more mature private company valued at about $350bn. It's projected to generate $15.5bn in revenue in 2025. This is driven by its dominant Falcon 9 launch services and rapidly growing Starlink satellite internet business. SpaceX's valuation implies roughly a 22.5 times multiple on forward revenue. This is broadly in line with Rocket Lab. Focusing on Rocket Lab, the company is projected to deliver rapid revenue growth over the next several years, with estimates rising from $573m in 2025 to $889 in 2026, $1.2bn in 2027, and $1.69bn in 2028. This represents annual growth rates consistently above 30%, and even a jump of nearly 77% in 2030. However, the number of analysts providing forecasts declines sharply after 2027, dropping from 11–14 analysts in the near term to just two or one by 2028 and 2030. The one analyst projecting as far as 2030 sees $4bn in revenue for the year. I had the chance to buy Rocket Lab shares at $15 just two months ago. I missed out as unfortunately my attention had been diverted elsewhere. However, I found another entry point. And personally, I see this as an investment to hold for a very long period. The space industry is still in its early innings, with enormous potential as satellite launches, lunar missions, and in-orbit services become increasingly mainstream. And like any investment, there are risks. Rocket Lab remains loss-making. It's expected to turn a profit in 2026, when it will trade at 620 times earnings. And while this moderates to 140 times in 2027, it's still expensive and introduces plenty of execution risk. However, I certainly believe UK investors should consider this one. It could be a real winner going forward. The post Investors should consider this growth stock… it's SpaceX's competition appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has positions in Rocket Lab. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Community collaboration crucial in addressing homelessness in Abilene
ABILENE, Texas () – Young professionals gathered at the Community Foundation of Abilene for an 'Abi Chat' during the Abilene Young Professionals luncheon. Networking took a purposeful turn to address homelessness through collaboration with the West Texas Homeless Network. The West Texas Homeless Network (WTHN) is a coalition of organizations dedicated to advocating for action that realigns systems and resources to end homelessness in Abilene, rather than merely managing it. The WTHN is neither a non-profit nor a for-profit organization; instead, it focuses on helping communities prevent and eliminate homelessness through collaboration and strategic planning. The Executive Director of Abilene Hope Haven shared why events like this are important in keeping the conversation with the public and continuing to address the needs of the Big Country Homeless community. 'We have a great network of people. We always are going to need to fill different gaps, depending on what's going on in the climate of our community. But we have a wealth of providers in the network that are really good at doing a holistic approach to those experiencing homelessness,' Horton shared. Horton says the Abilene community's wealth of resources and willingness to work together are its strengths. Whether a person needs help with mental health, food insecurity, substance abuse, or any number of issues that homeless neighbors face, the network is ready and willing to step in. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Forget 'biological age' tests — longevity experts are using an $800 under-the-radar blood test to measure aging in real-time
Doctors and scientists are using a blood plasma test to study longevity. The test measures proteins and can tell you about your organ health. This field of proteomics could one day help detect diseases like cancer before they start. Should you have that second cup of coffee? How about a little wine with dinner? And, is yogurt really your superfood? Scientists are getting closer to offering consumers a blood test that could help people make daily decisions about how to eat, drink, and sleep that are more perfectly tailored to their unique biology. The forthcoming tests could also help shape what are arguably far more important health decisions, assessing whether your brain is aging too fast, if your kidneys are OK, or if that supplement or drug you're taking is actually doing any good. It's called an organ age test, more officially (and scientifically) known as "proteomics" — and it's the next hot "biological age" marker that researchers are arguing could be better than all the rest. "If I could just get one clock right now, I'd want to get that clock, and I'd like to see it clinically available in older adults," cardiologist Eric Topol, author of the recent bestseller "Super Agers: An Evidence-Based Approach to Longevity," told Business Insider. Topol said armed with organ age test results, people could become more proactive stewards of their own health, before it's too late. "When we have all these layers of data, it's a whole new day for preventing the disease," Topol said. "You see the relationship with women's hormones. You see the relationship with food and alcohol. You don't ever get that with genes." A test like this isn't available to consumers just yet, but it's already being used by researchers at elite universities and high-end longevity clinics. They hope it can become a tool any doctor could use to assess patient health in the next few years. A startup called Vero, which was spun out of some foundational proteomics research at Stanford University, is hoping to beta test a proteomics product for consumers this year. "Knowing your oldest organ isn't the point; changing the trajectory is," Vero co-founder and CEO Paul Coletta told a crowd gathered at the Near Future Summit in Malibu, California, last month. Coletta told Business Insider Vero's not interested in doing "wealthcare." The company plans to make its test available to consumers for around $200 a pop, at scale. Their draw only requires one vial of blood. The big promise of proteomics is that it could be a more precise real-time tool for tracking important but subtle changes that emerge inside each of us as we age. Genetic testing can measure how our bodies are built, spotting vulnerabilities in a person's DNA that might predispose them to health issues. Standard clinical measurements like a person's weight, blood pressure, or cholesterol readings are a useful proxy for potential health issues. Then there are the increasingly popular "biological age" tests available to consumers at home. Most of those look at "epigenetic changes" — how environmental factors affect our gene expression. Proteomics does something different and new. It measures the product that our bodies make based on all those genetic and environmental inputs: proteins. It offers a live assessment of how your body is running, not just how it's programmed. If validated in the next few years, these tests could become key in early disease detection and prevention. They could help influence all kinds of medical decisions, from big ones like "What drugs should I take?" to little ones like "How does my body respond to caffeine or alcohol?" Some high-end longevity clinics are already forging ahead using proteomics to guide clinical recommendations, albeit cautiously. Dr. Evelyne Bischof, a longevity physician who treats patients worldwide, said she uses proteomic information to guide some of the lifestyle interventions she recommends to her patients. She may suggest a more polyphenol-rich diet to someone who seems to have high inflammation and neuroinflammation based on proteomic test results, or may even suggest they do a little more cognitive training, based on what proteomics says about how their brain is aging. Dr. Andrea Maier, a professor of medicine and functional aging at the National University of Singapore, told BI she uses this measurement all the time in her longevity clinics. For her, it's just a research tool, but if the results of her ongoing studies are decent, she hopes to be able to use it clinically in a few years' time. "We want to know what kind of 'ageotype' a person is, so what type of aging personality are you, not from a mental perspective, but from a physical perspective," Maier said. "It's really discovery at this moment in time, and at the edge of being clinically meaningful." "Once we have that validated tool, we will just add it to our routine testing and we can just tick the box and say, 'I also want to know if this person is a cardiac ager, or a brain ager, or a muscle ager' because now we have a sensitive parameter — protein — which can be added," Maier said. The two big-name proteomics tests are Olink and SOMAscan. For now, their high-end screening costs around $400-$800 per patient. "I'm losing lots of money at the moment because of proteomics for clinical research!" Maier said. Top aging researchers at Stanford and Harvard are pushing the field forward, racing to publish more novel insights about the human proteome. The latest findings from Harvard aging researcher Vadim Gladyshev's lab, published earlier this year, suggest that as we age, each person may even stand to benefit from a slightly different antiaging grocery list. To research this idea, Gladyshev looked at proteins in the blood of more than 50,000 people in the UK, all participants in the UK Biobank who are being regularly tested and studied to learn more about their long-term health. He tracked their daily habits and self-reported routines like diet, occupation, and prescriptions, comparing those details to how each patient's organs were aging. He discovered some surprising connections. Yogurt eating, generally speaking, tended to be associated with better intestinal aging but had relatively no benefit to the arteries. White wine drinking, on the other hand, seemed to potentially confer some small benefit to the arteries while wreaking havoc on the gut. "The main point is that people age in different ways in different organs, and therefore we need to find personalized interventions that would fit that particular person," Gladyshev told BI. "Through measuring proteins, you assess the age of different organs and you say, 'OK, this person is old in this artery.'" For now, there's too much noise in the data to do more. Dr. Pal Pacher, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism who studies organ aging and injuries, told BI that proteomics is simply not ready for clinical use yet. There's just too much noise in the data. But he imagines a future where a more sophisticated protein clock could help link up which people may be most vulnerable to diseases like early cancer, kidney disease, and more. (A California-based proteomics company called Seer announced last weekend that it is partnering with Korea University to study whether proteomics can help more quickly diagnose cancer in young people in their 20s and 30s.) "How beautiful could it be in the future?" Maier said. "Instead of three hours of clinical investigation, I would have a tool which guides me much, much better, with more validity towards interventions." Read the original article on Business Insider
